Claim Details

View detailed information about this claim and its related sources.

Back to Claims

Claim Information

Complete details about this extracted claim.

Claim Text
Dr. Babak Orandi, an obesity medicine specialist and transplant surgeon at N.Y.U. Langone Health, is the lead author of the study published Tuesday in the journal Obesity.
Simplified Text
Dr. Babak Orandi, an obesity medicine specialist and transplant surgeon at N.Y.U. Langone Health, is the lead author of the study published on September 22, 2026, in the journal Obesity.
Confidence Score
1.000
Claim Maker
The New York Times
Context Type
News Article
Context Details
{
    "date": "2026-09-22",
    "person": "Dr. Babak Orandi",
    "journal": "Obesity",
    "affiliation": "N.Y.U. Langone Health"
}
Subject Tags
Medical Professional Researcher Study Author
UUID
25fa1b32-0b4a-484d-9ea7-b9b6f9559e9c
Vector Index
✗ No vector
Created
September 25, 2026 at 10:06 AM (2 weeks ago)
Last Updated
September 25, 2026 at 10:06 AM (2 weeks ago)

Original Sources for this Claim (1)

All source submissions that originally contained this claim.

Screenshot of https://nytimes.com/2026/09/22/well/ozempic-glp1-medical-reason.html
GLP-1 Prescriptions for People With No Medical Need Are Climbing
Completed News
7 claims
2 weeks ago
https://nytimes.com/2026/09/22/well/ozempic-glp1-medical-reason.html

A new study analyzing over 92 million U.S. adult medical records found more than 1.1 million people taking GLP-1 medications without an apparent medical reason like obesity or diabetes. Doctors express concern over off-label use, potential risks, and the cultural phenomenon surrounding these drugs.

GLP-1 drugs Ozempic Off-label prescriptions Weight loss drugs Medical ethics Public health Obesity Diabetes

Similar Claims (5)

Other claims identified as semantically similar to this one.